Skip to main content

Drug Interactions between binimetinib and risdiplam

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

binimetinib risdiplam

Applies to: binimetinib and risdiplam

Consumer information for this interaction is not currently available.

MONITOR: Theoretical concerns exist that oculotoxic effects of risdiplam, observed in monkeys, may be additive with those of other drugs that are associated with retinotoxicity. Chronic treatment of monkeys with risdiplam showed photoreceptor degeneration starting in the periphery of the retina. Upon cessation of treatment, the effects on the retinogram were partially reversible but the retinal degeneration, with peripheral photoreceptor loss, was irreversible. A no-effect dose for the retinal findings (1.5 mg/kg/day) in monkeys was associated with plasma exposures (AUC) like that in humans at the maximum recommended human dose (MRHD) of 5 mg. However, the potential for synergistic effects of concomitant administration of risdiplam with retinotoxic drugs has not been studied.

MANAGEMENT: Some authorities (AU) recommend caution when risdiplam is used concomitantly with known or suspected retinotoxic drugs. These drugs may include infigratinib, selumetinib, cobimetinib, vigabatrin, chloroquine, hydroxychloroquine, thioridazine and deferoxamine.

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer